Short Biotechnology Quotes

An article published in the magazine Bioscience, Biotechnology and Biochemistry in 2009 reported that drinking diluted apple everyday for as short as 3 months decreases abdominal fat, waist circumference and the level of blood triglycerides. It has been proven that high levels of blood triglycerides and abdominal fat are related to high blood pressure, stroke and heart attack. The malic acid content of apple cider vinegar helps unclog each artery in the body. The beta-carotene in apple cider vinegar also helps fat to be metabolized for energy.

P2 - We are well on the way in a number of areas. Both billionaires and big Pharma are getting increasingly interested and money is starting to pour into research because it is clear we can see the light at the end of the tunnel which to investors equates to return on investment. Numerous factors will drive things forward and interest and awareness is increasing rapidly among both scientists, researchers and the general population as well as wealthy philanthropists. The greatest driving force of all is that the baby boomers are aging and this will place increasing demands on healthcare systems. Keep in mind that the average person costs more in medical expenditure in the last year of their life than all the other years put together. Also, the number of workers is declining in most developed countries which means that we need to keep the existing population working and productive as long as possible. Below are a list which are basically all technologies potentially leading to radical life extension with number 5 highlighted which I assume might well be possible in the second half of the century: 1. Biotechnology - e.g stem cell therapies, enhanced autophagy, pharmaceuticals, immunotherapies, etc 2. Nanotechnology - Methods of repairing the body at a cellular and molecular level such as nanobots. 3. Robotics - This could lead to the replacement of increasing numbers of body parts and tends to go hand in hand with AI and whole brain emulation. It can be argued that this is not life extension and that it is a path toward becoming a Cyborg but I don’t share that view because even today we don’t view a quadriplegic as less human if he has four bionic limbs and this will hold true as our technology progresses. 4. Gene Therapies - These could be classified under the first category but I prefer to look at it separately as it could impact the function of the body in very dramatic ways which would suppress genes that negatively impact us and enhance genes which increase our tendency toward longer and healthier lives. 5. Whole brain emulation and mindscaping - This is in effect mind transfer to a non biological host although it could equally apply to uploading the brain to a new biological brain created via tissue engineering this has the drawback that if the original brain continues to exist the second brain would have a separate existence in other words whilst you are identical at the time of upload increasing divergence over time will be inevitable but it means the consciousness could never die provided it is appropriately backed up. So what is the chance of success with any of these? My answer is that in order for us to fail to achieve radical life extension by the middle of the century requires that all of the above technologies must also fail to progress which simply won't happen and considering the current rate of development which is accelerating exponentially and then factoring in that only one or two of the above are needed to achieve life extension (although the end results would differ greatly) frankly I can’t see how we can fail to make enough progress within 10-20 years to add at least 20 to 30 years to current life expectancy from which point progress will rapidly accelerate due to increased funding turning aging at the very least into a manageable albeit a chronic incurable condition until the turn of the 22nd century. We must also factor in that there is also a possibility that we could find a faster route if a few more technologies like CRISPR were to be developed. Were that to happen things could move forward very rapidly. In the short term I'm confident that we will achieve significant positive results within a year or two in research on mice and that the knowledge acquired will then be transferred to humans within around a decade. According to ADG, a dystopian version of the post-aging world like in the film 'In Time' not plausible in the real world: "If you CAREFULLY watch just the first

Continuing to do research on genetic modification, and occasionally using successfully modified organisms for specific purposes such as the production of expensive drugs, make good sense. Helping developing countries to produce more food is a worthy aim, but it is sometimes used as an excuse for an alternative agenda, or as a convenient way to demonise opponents. There is little doubt that the technology needs better regulation: I find it bizarre that standard food safety tests are not required, on the grounds that the plants have not been changed in any significant way, but that the innovations are so great that they deserve patent protection, contrary to the long-standing view that naturally occurring objects and substances cannot be patented. Either it’s new, and needs testing like anything else, or it’s not, and should not be patentable. It is also disturbing, in an age when commercial sponsors blazon their logos across athletes’ shirts and television screens, that the biotechnology industry has fought a lengthy political campaign to prevent any mention of their product being placed on food. The reason is clear enough: to avoid any danger of a consumer boycott. But consumers are effectively being force-fed products that they may not want, and whose presence is being concealed. Our current understanding of genetics and ecology is inadequate when it comes to the widespread use of genetically modified organisms in the natural environment or agriculture. Why take the risk of distributing the material, when the likely gains for most of us – as opposed to short-term profits for biotechnology companies – are tiny or non-existent?